نتایج جستجو برای: modifying drugs

تعداد نتایج: 257803  

Journal: :Rheumatic diseases clinics of North America 2012
Anna Gramling James R O'Dell

The prognosis for the patient with newly diagnosed rheumatoid arthritis (RA) has dramatically changed over the last two decades. If a patient is diagnosed and treated early by a rheumatologist with the goal of remission or low disease activity, half of patients can expect to achieve remission while taking their disease-modifying antirheumatic drugs. This article discusses the initial therapy in...

2009
Mathilde Benhamou Nathalie Rincheval Carine Roy Violaine Foltz Sylvie Rozenberg Jean Sibilia Thierry Schaeverbeke Philippe Ravaud Bruno Fautrel

Journal: :Clinical and experimental rheumatology 1999
W Bensen W Bensen

Combination disease-modifying antirheumatic drug therapy with methotrexate and hydroxychloroquine has changed the course of rheumatoid arthritis. Better management requires "front of the line" care, effective drug combinations, and a goal of "Personal Best." The Pincus phenomenon--the discrepancy between subjective satisfaction and objective progression--may be minimized in clinical practice by...

Journal: :The Journal of rheumatology 2010
Rui-Xue Leng Dong-Qing Ye

Journal: :Rheumatology Forum 2022

Leki modyfikujące przebieg choroby stanowią podstawę leczenia przewlekłych zapaleń stawów, hamują postęp i mogą doprowadzić do stanu remisji. Większość z tych leków to preparaty o działaniu immunosupresyjnym oraz leki biologiczne. Pojawiają się doniesienia dodatkowych, oprócz efektu przeciwzapalnego, działaniach preparatów, w tym przeciwcukrzycowym. Celem pracy jest przedstawienie dostępnych ob...

2016
D.S. Courvoisier D. Alpizar-Rodriguez J.E. Gottenberg M.V. Hernandez F. Iannone E. Lie M.J. Santos K. Pavelka C. Turesson X. Mariette D. Choquette M.L. Hetland A. Finckh

BACKGROUND Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD). METHODS Pooled analysis of nine national registries of patients with diagnosis of RA, who initiated Abatacept and had at least two measures of disease ac...

2014
Huabin F Zhang Geneviève Gauthier Robert Hiscock Jeffrey R Curtis

INTRODUCTION This study aimed to describe treatment changes (discontinuation, switching, and therapy add-on) following the initiation of biologic or nonbiologic oral disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis (PsA) patients. METHODS Adult patients with ≥2 PsA diagnoses from physician office visits, initiated on a biologic or nonbiologic oral DMARD, were selected fro...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید